Navigation Links
Greasing interferon's gears may pave way to greater therapeutic benefits, fewer side effects

nterferon -- a critical protein that mediates the body's defense against a wide variety of infectious agents and tumors -- may soon have greater therapeutic value as the result of a new study by researchers at Washington University School of Medicine in St. Louis.

"Essentially, we found a way to grease the gears that drive the interferon signal," says Michael J. Holtzman, M.D., the Selma and Herman Seldin Professor of Medicine and director of the Division of Pulmonary and Critical Care Medicine.

The researchers modified the structure of a protein called Stat1, which relays signals from interferon at the cell surface to genes in the cell nucleus. The modification up shifted Stat1's response to interferon.

The study will appear in the October 7, 2005 issue of the Journal of Biological Chemistry and was selected as the journal's Paper of the Week, which recognizes the top one percent of the journal's papers in significance and overall importance.

The development of a mechanism to tweak Stat1's responsiveness may prove particularly useful for patients with such disorders as hepatitis C, multiple sclerosis and many types of systemic cancer, who currently benefit from interferon treatment, but sometimes find it difficult to tolerate the side effects of the high doses required.

"We reasoned that if we could enhance the way interferon produces its beneficial defensive effects, the body could respond to its normal level of interferon and receive enhanced benefit without side effects," Holtzman says.

The group engineered a mutant Stat1 protein in which the identities of two amino acids were switched. Investigations conducted on cells growing in culture showed that the altered Stat1 proteins reacted more efficiently to the presence of both type I and type II interferons. Further tests revealed that the souped-up Stat1 recruited more of a specific protein it needs to pass on the interferon signal, essentially raising the spee d limit on signal transmission.

"Ordinarily, the interferon signaling system's rate may be slowed because this helper protein interacts with Stat1 at less than the maximum amount," Holtzman says. "It's possible that the maximal setting would be harmful in the long term, because too much interferon could lead to inflammatory diseases. But we may find advantages to increasing Stat1 action in the short term using drug treatments."

Such therapies could allow physicians to turn up the effect of interferon temporarily to treat infections or other disorders and then to turn it back down to normal levels when the patient is cured.

"The potential for this 'rheo-Stat' strategy is exciting," Holtzman says. "As an example, one could improve Stat1 efficiency during the winter months in patients at risk of developing serious viral infections, including children with asthma, heart disease or compromised immune systems."

It may be possible, as well, to screen patients for levels of Stat1 responsiveness and use the same treatment strategy to correct low levels of response, according to Holtzman. The researchers are currently screening newborn infants for levels of Stat1 action and tracking their susceptibility to viral infection.

In addition, the group is studying transgenic mice engineered to carry the same Stat1 mutations that were examined in cells. In this way, the researchers can investigate the benefits of hyper-responsive Stat1 for infection control and cancer treatment in a living organism. These studies lay the foundation for the development of human treatments that use drugs that increase Stat1 responsiveness and consequently enhance the benefits of interferon produced naturally in the body or given as treatment.


'"/>

Source:Washington University School of Medicine


Related biology news :

1. Great (taste) expectations: Study shows brain anticipates taste, shifts gears
2. Forsyth scientists gain greater understanding of how embryos differentiate left from right
3. Deep-rooted plants have much greater impact on climate than experts thought
4. The diversity of marine life in the Gulf of Maine region is much greater than previously thought
5. The higher the hierarchy, the greater the aggression
6. Higher levels of obesity associated with greater health risks
7. Underweight women at greater risk of miscarriage
8. Anthrax attack posed greater potential threat than thought
9. Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems
10. Study reveals candidate targets for anti-retroviral therapeutics
11. Tetanus toxin found to have therapeutic properties
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2016)... Calif. , Feb. 2, 2016  Based ... market, Frost & Sullivan recognizes US-based Intelligent Retinal ... Frost & Sullivan Award for New Product Innovation. ... in North America , is ... the rapidly growing diabetic retinopathy market. The IRIS ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
(Date:1/28/2016)... 28, 2016 Synaptics (NASDAQ: SYNA ), a leading ... second quarter ended December 31, 2015. --> ... fiscal 2016 increased 2 percent compared to the comparable quarter last ... fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... for the first quarter of fiscal 2016 grew 9 percent over ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... Sunnyvale, CA (PRWEB) , ... February 09, 2016 ... ... will present its latest innovations on its free and validated Electronic Data Capture ... Booth #81 the Outsourcing in Clinical Trials West Coast 2016 Conference in San ...
(Date:2/9/2016)... ... 2016 , ... The American Academy of Thermology (AAT) has announced ... AAT Member Certification Qualification Course for Technicians via a two part webinar on July ... a detailed review of hardware, software, and camera setup/operations, aligns with the in-person member ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... Vice President for Public Policy for the National Organization for Rare Disorders (NORD). ... groups to ensure their voices are heard throughout the drug regulatory review process. ...
(Date:2/9/2016)... , Feb. 9, 2016 This market research ... current and future prospects of the market in terms ... include companies engaged in the manufacture of microbiology culture ... summary with a market snapshot providing the overall information ... this report. This section also provides the overall information ...
Breaking Biology Technology: